Kodiak Sciences Inc. Announces Positive Phase 3 Results for Two AMD Drugs

What Happened

• Kodiak Sciences Inc. filed an 8-K (Item 8.01) on September 28, 2026, announcing that the primary endpoints were met in its Phase 3 DAYBREAK study for two investigational treatments for wet age-related macular degeneration: Zenkuda (tarcocimab tedromer) and tabirafusp-ted (KSI-501). The company issued a press release on the same date; that release is attached to the filing as Exhibit 99.1.

Key Details

• Filing date: September 28, 2026 (Form 8-K, Item 8.01).
• Study: Phase 3 DAYBREAK in patients with wet age-related macular degeneration (wet AMD).
• Agents: Zenkuda (tarcocimab tedromer) and tabirafusp-ted (KSI-501 / KSI-501).
• Press release summarizing the results included as Exhibit 99.1 to the 8-K.

Why It Matters

• Meeting primary endpoints in a Phase 3 trial is a major clinical milestone for a drug development program and may be required before a company pursues regulatory submissions or commercialization steps. Investors should view this as significant clinical progress for Kodiak’s wet AMD programs.
• The 8-K provides the headline outcome but not detailed efficacy or safety data; shareholders and potential investors should watch for Kodiak’s full data disclosures, regulatory plans, and any follow-up announcements for details that could affect valuation and timelines.